Immix Biopharma, Inc.
Extracted from this filing and checked against the source text.
Immix Biopharma, Inc. shareholders approved Ratification of KMJ Corbin & Company LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
The result of the votes to approve KMJ was as follows: For Against Abstain Broker Non-Votes 9,497,865 36,813 7,792 0View on SEC.gov
Immix Biopharma, Inc. shareholders approved Election of seven directors at the 2023-06-07 meeting.
All of the seven nominees for director were elected to serve until the next annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the seven directors were as follows: Directors For Withhold Broker Non-Votes Ilya Rachman 7,600,072 22,447 1,919,951 Gabriel Morris 7,457,001 165,518 1,919,951 Jason Hsu 7,560,452 62,066 1,919,952 Magda Marquet 7,491,766 130,753 1,919,951 Helen C. Adams 7,488,906 133,612 1,919,952 Carey Ng 7,585,080 37,438 1,919,952 Jane Buchan 7,495,642 126,877 1,919,951View on SEC.gov
Immix Biopharma, Inc. shareholders approved Approval of Immix Biopharma, Inc. Amended and Restated 2021 Omnibus Equity Incentive Plan at the 2023-06-07 meeting.
The result of the votes to approve the Amended and Restated 2021 Plan was as follows: For Against Abstain Broker Non-Votes 7,315,768 295,959 10,792 1,919,951View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.